Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.

Andrew H Wei, Gail J Roboz, Herve Dombret, Hartmut Dohner, Andre C Schuh, Pau Montesinos, Dominik Selleslag, Sergey N Bondarenko, Thomas Prebet, Yinzhi Lai, Barry Skikne, C L Beach, Farhad Ravandi

Haematologica 2023 October 2

No abstract text is available yet for this article.

Full text links

We have located links that may give you full text access.

Show additional links to paperHide additional links to paper

PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app